Product Overview
Pseudotyped VSV-SARS-CoV-2 S-ΔG-GFP (Omicron variant, BA.4/BA.5) encodes the antigenomic-sense (or positive-sense) RNA of a replicaton-restricted recombinant vesicular stomatitis virus (rVSV) in which the glycoprotein (G) gene has been replaced with SARS-CoV-2 spike protein (T19I, LPPA24S, HV69del, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K). Because the infectivity of Pseudotyped VSV-SARS-CoV-2 S-ΔG-GFP is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices.The pseudotype VSV particles encode GFP together with the VSV nucleocapsid (N), phosphoprotein (P), glycoprotein (G), and large polymerase subunit (L) in their pVSV-ΔG vector. When the VSV pseudovirus infect the target cells, GFP expression is proportional to the number of cells that were infected.
Application Notes
We recommended to use 2-5 μL pseudotyped virus per 1E+04 293T cells for in vitro assay. Due to differences in cell status,the best infection conditions and MOI should be determined by the end user. The virus can be diluted with cell culture medium if needed.
Keywords
SARS-CoV-2; Coronavirus; SARS-CoV; SARS-CoV-2 Envelope Protein; SARS-CoV-2 Envelope glycoprotein; SARS-CoV-2 glycoprotein; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Syndrome-2; Severe Acute Respiratory Syndrome glycoprotein; Severe Acute Respiratory Syndrome-2 glycoprotein; SARS-CoV-2 Pseudovirus; SARS-CoV Pseudovirus; SARS Pseudovirus;